BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Konda VJA, Souza RF. Biomarkers of Barrett's Esophagus: From the Laboratory to Clinical Practice. Dig Dis Sci. 2018;63:2070-2080. [PMID: 29713984 DOI: 10.1007/s10620-018-5088-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Lv J, Guo L, Wang JH, Yan YZ, Zhang J, Wang YY, Yu Y, Huang YF, Zhao HP. Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett’s esophagus. World J Gastroenterol 2019; 25(2): 233-244 [PMID: 30670912 DOI: 10.3748/wjg.v25.i2.233] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
2 Dugalic P, Djuranovic S, Pavlovic-Markovic A, Dugalic V, Tomasevic R, Gluvic Z, Obradovic M, Bajic V, Isenovic ER. Proton Pump Inhibitors and Radiofrequency Ablation for Treatment of Barrett's Esophagus. Mini Rev Med Chem 2020;20:975-87. [PMID: 31644405 DOI: 10.2174/1389557519666191015203636] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 McDaniel M, Conran RM. Educational Case: Barrett Esophagus. Acad Pathol 2019;6:2374289519848089. [PMID: 31192298 DOI: 10.1177/2374289519848089] [Reference Citation Analysis]
4 Jones B, Wani S. Endoscopic Eradication Therapy for Barrett's Neoplasia: Where Do We Stand a Decade Later? Curr Gastroenterol Rep 2020;22:61. [PMID: 33277663 DOI: 10.1007/s11894-020-00799-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Steele D, Baig KKK, Peter S. Evolving screening and surveillance techniques for Barrett's esophagus. World J Gastroenterol 2019; 25(17): 2045-2057 [PMID: 31114132 DOI: 10.3748/wjg.v25.i17.2045] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
6 Fassan M, Realdon S, Cascione L, Hahne JC, Munari G, Guzzardo V, Arcidiacono D, Lampis A, Brignola S, Dal Santo L, Agostini M, Bracon C, Maddalo G, Scarpa M, Farinati F, Zaninotto G, Valeri N, Rugge M. Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett's carcinogenesis. Pathol Res Pract 2020;216:152907. [PMID: 32131978 DOI: 10.1016/j.prp.2020.152907] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Kolb JM, Wani S. Endoscopic eradication therapy for Barrett's oesophagus: state of the art. Curr Opin Gastroenterol 2020;36:351-8. [PMID: 32487852 DOI: 10.1097/MOG.0000000000000650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Porter RJ, Murray GI, Brice DP, Petty RD, McLean MH. Novel biomarkers for risk stratification of Barrett's oesophagus associated neoplastic progression-epithelial HMGB1 expression and stromal lymphocytic phenotype. Br J Cancer 2020;122:545-54. [PMID: 31831860 DOI: 10.1038/s41416-019-0685-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
9 Triggs JR, Falk GW. Best Practices in Surveillance for Barrett's Esophagus. Gastrointest Endosc Clin N Am 2021;31:59-75. [PMID: 33213800 DOI: 10.1016/j.giec.2020.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lohse I, Al-Ali H, Volmar CH, D Alvarez Trotta A, Brothers SP, Capobianco AJ, Wahlestedt C. Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinoma. PLoS One 2018;13:e0203173. [PMID: 30212533 DOI: 10.1371/journal.pone.0203173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Espinoza JA, Riquelme I, Sagredo EA, Rosa L, García P, Bizama C, Apud-Bell M, Leal P, Weber H, Benavente F, Vargas S, Romero D, Kalergis AM, Roa JC. Mucin 5B, carbonic anhydrase 9 and claudin 18 are potential theranostic markers of gallbladder carcinoma. Histopathology 2019;74:597-607. [PMID: 30565710 DOI: 10.1111/his.13797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Campos VJ, Mazzini GS, Juchem JF, Gurski RR. Neutrophil-Lymphocyte Ratio as a Marker of Progression from Non-Dysplastic Barrett's Esophagus to Esophageal Adenocarcinoma: a Cross-Sectional Retrospective Study. J Gastrointest Surg 2020;24:8-18. [PMID: 31745889 DOI: 10.1007/s11605-019-04456-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]